Dr Reddy's Labs plans to roll out cheaper Wegovy copycat across 87 countries in 2026: CEO
Written By : Ruchika Sharma
Medically Reviewed By : Dr. Kamal Kant Kohli
Published On 2025-07-25 11:00 GMT | Update On 2025-07-25 11:00 GMT
Advertisement
Hyderabad: Dr. Reddy's Laboratories is gearing up to shake up the global weight-loss drug market with the launch of an affordable copycat version of Wegovy, the blockbuster weight-loss drug from Novo Nordisk. The Indian pharmaceutical giant plans to introduce the drug in 87 countries next year, the Indian drugmaker's CEO, Erez Israeli, said.
The company is aiming to capture a slice of the lucrative global obesity drug market, projected to generate around $150 billion in sales by the early 2030s.
Dr Reddy's initially plans to launch the generic version of semaglutide - the active ingredient of Novo's Wegovy and diabetes medicine Ozempic - in Canada, India, Brazil, Turkey and other emerging markets, subject to patent expiry, Israeli said.
"U.S. and Europe will open later... (and) all the other Western markets will be open between 2029 to 2033," Israeli said a press conference to discuss the company's earnings.
Novo launched Wegovy in India last month, following Lilly's Mounjaro launch for weight-loss and diabetes management.
The drugs belong to a class called GLP-1 receptor agonists that help control blood sugar and slow digestion, making people feel fuller for longer.
Dr Reddy's also aims to launch 26 GLP-1 drugs within the next decade, Israeli said.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.